Advertisement
Findings may guide future research and personalized treatments
Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment
Real-world results reporting aims to make treatments safer and more effective
Ongoing clinical validation in diverse populations refine breast cancer risk substratification
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings strengthen evidence for risk-reducing procedures
Offers a new option for patients 60 and older with relapsed/refractory disease
Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance
Advertisement
Advertisement